ADC Therapeutics/ADCT

$5.04

-1.95%
-
1D1W1MYTD1YMAX

About ADC Therapeutics

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Ticker

ADCT

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Ameet Mallik

Employees

317

Headquarters

Epalinges, Switzerland

ADC Therapeutics Metrics

BasicAdvanced
$377.41M
Market cap
-
P/E ratio
-$2.20
EPS
1.73
Beta
-
Dividend rate

What the Analysts think about ADC Therapeutics

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
83.53% upside
High $14.00
Low $6.00
$5.04
Current price
$9.25
Average price target

ADC Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-331.94% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$14.4M
-25%
Net income
$-47.8M
1.49%
Profit margin
-331.94%
35.31%

ADC Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.55%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.30
-$0.74
-$0.58
-$0.58
-
Expected
-$0.29
-$0.67
-$0.46
-$0.63
-$0.50
Surprise
4.6%
10.45%
26.87%
-8.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell ADC Therapeutics stock

Buy or sell ADC Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing